Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Singer, S; Semrau, S; Golcher, H; Fechner, K; Kallies, A; Zapata, Bonilla, S; Grützmann, R; Fietkau, R; Kluba, T; Jentsch, C; Andreou, D; Bornhäuser, M; Schmitt, J; Schuler, MK; Eichler, M.
The health-related quality of life of sarcoma patients treated with neoadjuvant versus adjuvant radiotherapy - Results of a multi-center observational study.
Radiother Oncol. 2023; 189:109913 Doi: 10.1016/j.radonc.2023.109913
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Andreou Dimosthenis
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: AIM: The sequence of radiotherapy and resection in patients with soft tissue sarcomas is usually discussed on an individual basis. Better understanding of potential differences of health-related quality of life (QoL) between patients undergoing adjuvant (ART) versus neoadjuvant radiotherapy (NART) is therefore helpful for clinical decision making. METHODS: Adult sarcoma patients from 39 hospitals completed the European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30). Differences in global QoL, physical functioning, role functioning, fatigue, pain, and insomnia between ART versus NART were investigated with multivariate regression, adjusting for age, gender, chemotherapy, grading, stage, tumor location, recurrence/distant metastasis, sarcoma type, time since last treatment, and treatment status using validated thresholds. RESULTS: A total of 1110 patients participated. Of them, 340 had received radiotherapy (NART: n = 95, 28%; ART: n = 245, 72%). Global QoL was 59.3 on average after NART and 60.5 after ART (B_adj = 1.0, p = 0.74). Physical functioning was 65.9 compared to 70.5 (B_adj = 4.2; p = 0.16), role function 48.8 vs. 56.7 (B_adj = 7.0, p = 0.08), fatigue 47.5 vs. 45.4 (B_adj = -1.2; p = 0.71), pain 40.2 vs. 34.1 (B_adj = -6.8; p = 0.08), and insomnia 33.7 vs. 41.6 (B_adj = 5.5, p = 0.16). Among patients with NART, clinically relevant QoL impairments were less frequent 2 years after treatment compared to < 2 years thereafter (n = 6 vs. n = 4 on average). CONCLUSION: There is little evidence for QoL differences in most domains and overall QoL between the two irradiation groups. However, patients after NART might experience worse role functioning and pain but fewer problems with insomnia compared to patients after ART.
Find related publications in this database (using NLM MeSH Indexing): Adult - administration & dosage; Humans - administration & dosage; Neoadjuvant Therapy - adverse effects; Pain - etiology; Quality of Life - administration & dosage; Radiotherapy, Adjuvant - adverse effects; Sarcoma - radiotherapy; Sleep Initiation and Maintenance Disorders - etiology; Male - administration & dosage; Female - administration & dosage
Find related publications in this database (Keywords): Liposarcoma; Leiomyosarcoma; Neoplasms, Connective and Soft Tissue; Neoadjuvant Therapy; Radiotherapy, Adjuvant; Patient Reported Outcome Measures